Physician profile
Olusegun A Ogunlesi
NPI 1013182013
$3,496.12
in general payments reported to CMS, 2019-2025
24 companies · $633 in 2025
The $633 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $329 · 2021: $525 · 2022: $508 · 2023: $736 · 2024: $609 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,951 · Education: $27.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,951.22 |
| Education | $27.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $619.19 | 2019-2025 | Pifeltro, Zerbaxa, Dificid |
| Smith+Nephew, INC. | $571.89 | 2021-2025 | Collagenase Santyl, Grafix Pl |
| Abbvie INC. | $323.47 | 2021-2025 | |
| Gilead Sciences, INC. | $271.50 | 2019-2024 | Veklury |
| Organogenesis INC. | $221.41 | 2019-2025 | Puraply Wound Matrix |
| Viiv Healthcare Company | $219.47 | 2022-2025 | Dovato |
| Kerecis Limited | $197.39 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Insmed, INC. | $181.20 | 2019-2025 | Arikayce |
| Melinta Therapeutics, LLC | $153.49 | 2021-2023 | Vabomere, Kimyrsa, Orbactiv |
| Convatec INC. | $150.52 | 2019-2025 | |
| Shionogi INC | $138.59 | 2021-2025 | Fetroja |
| Mimedx Group, INC. | $87.57 | 2024 | |
| Aimmune Therapeutics, INC. | $72.37 | 2023-2025 | Vowst |
| Pfizer INC. | $59.41 | 2019-2023 | |
| Ferring Pharmaceuticals INC. | $41.20 | 2022-2024 | Rebyota |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $39.92 | 2021-2024 | Tcc-Ez |
| La Jolla Pharmaceutical Company | $32.21 | 2021-2022 | |
| Allergan, INC. | $26.05 | 2020 | |
| Tactile Systems Technology INC | $22.88 | 2025 | Flexitouch Plus, Nimbl |
| Acell, INC. | $17.37 | 2020 | |
| Nabriva Therapeutics, Plc | $14.90 | 2021 | |
| Adma Biomanufacturing LLC | $14.00 | 2022 | |
| Urgo Medical North America, LLC | $13.00 | 2023 | Urgok2, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Aroa Biosurgery Incorporated | $7.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olusegun Ogunlesi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.